Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2009
Reporting Period: The filing announces the issuance of a press release containing financial results for the three and six months ended June 30, 2009.
Key Financial Metrics
This Form 8-K serves as a notification of the release of financial results and does not contain specific numerical data within the text provided. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are contained in the attached press release (Exhibit 99.1), which is not included in the source text. Therefore, the filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing does not detail specific material changes versus prior periods. It solely references the publication of results for the periods ended June 30, 2009.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that management issued a press release on August 7, 2009, to report financial results.
Legal Status of Exhibit: The press release (Exhibit 99.1) is furnished under Item 2.02 and is explicitly not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not subject to the liabilities of that section and shall not be deemed incorporated by reference in any other filings.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific revenue, net loss, and cash position figures for the three and six months ended June 30, 2009.
- Verify the company's cash runway and burn rate, as these are critical for a biotechnology firm not reporting specific numbers in this summary document.
- Check for any forward-looking statements or guidance regarding clinical trial progress or partnership milestones in the full press release.
- Confirm the status of the company's debt obligations and liquidity position as detailed in the full financial report.